Attomolar detection of botulinum toxin type A in complex biological matrices

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Bagramyan, Karine ^a   Barash, Jason R ^b   Arnon, Stephen S ^b   Kalkum, Markus ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Infant Botulism Treatment and Prevention Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; METALLOPROTEINASE; TRYPSIN;

ANALYTIC METHOD; ARTICLE; ASSAY WITH A LARGE IMMUNOSORBENT SURFACE AREA; BIOASSAY; CARROT; ENZYME ACTIVITY; ENZYME SUBSTRATE; IMMUNOASSAY; INTERMETHOD COMPARISON; MILK; PROCESS OPTIMIZATION; REACTION TIME; SENSITIVITY AND SPECIFICITY; SERUM; TEMPERATURE; TOXIN ANALYSIS; ANIMAL; HUMAN; KINETICS; METHODOLOGY; MOUSE;

DAUCUS CAROTA;

ANIMALS; BIOLOGICAL ASSAY; BOTULINUM TOXIN TYPE A; HUMANS; KINETICS; MICE;

EID: 44349120485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002041     Document Type: Article

References (56)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. Jama 285: 1059-1070.
2. Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86-94.
3. Long SS (2007) Infant botulism and treatment with BIG-IV (BabyBIG®. Pediatr Infect Dis J 26: 261-262.
4. Koepke R, Sobel J, Arnon, S S (2008) Global occurrence of infant botulism, 1976-2006. Pediatrics; [in press].
5. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354: 462-471.
6. Werner SB, Passaro D, McGee J, Schechter R, Vugia DJ (2000) Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infec Dis 31: 1018-1024.
7. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S (2004) Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 10: 1606-1611.
8. Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, et al. (2006) Botulism in four adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296: 2476-2479.
9. Partikian A, Mitchell WG (2007) Iatrogenic botulism in a child with spastic quadriparesis. J Child Neurol 22: 1235-1237.
10. Crowner BE, Brunstrom JE, Racette BA (2007) Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol 30: 310-313.
11. Beseler-Soto B, Sanchez-Palomares M, Santos-Serrano L, Landa-Rivera L, Sanantonio-Valdearcos F, et al. (2003) [Iatrogenic botulism: a complication to be taken into account in the treatment of child spasticity]. Rev Neurol 37: 444-446.
12. Jankovic, J (2004) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75: 951-957.
13. Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56: 80-99.
14. Wein LM, Liu Y (2005) Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A 102: 9984-9989.
15. Sakaguchi G (1982) Clostridium botulinum toxins. Pharmacol Ther 19: 165-194.
16. Chen F, Kuziemko GM, Stevens RC (1998) Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun 66: 2420-2425.
17. Sharma SK, Ranizan MA, Singh KR (2003) Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 41: 321-331.
18. Zhang L, Lin WJ, Li S, Aoki KR (2003) Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene 315: 21-32.
19. Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8 Suppl 5: 21-29.
20. Melling J, Hambleton P, Shone CC (1988) Clostridium botulinum toxins: nature and preparation for clinical use. Eye 2 (Pt 1): 16-23.
21. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80: 717-766.
22. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum, neurotoxin type A and implications for toxicity. Nat Struct Biol 5: 898-902.
23. Kurazono H, Mochida S, Binz T, Eisel U, Quanz M, et al. (1992) Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botalinum neurotoxin type A. J Biol Chem 267: 14721-14729.
24. Cai S, Sarkar HK, Singh BR (1999) Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 38: 6903-6910.
25. Cai S, Singh BR (2001) Role of the disulfide cleavage induced molten globule state of type A britulinum neurotoxin in its endopeptidase activity. Biochemistry 40: 15327-15333.
26. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage ofsynaptobrevin. Nature 359: 832-835.
27. Schiavo G, Rossetto O, Catsicas S, Polverino de Lantern P, DasGupta BR, et al. (1993) Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E.J Biol Chem 268: 23784-23787.
28. Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, et al. (1993) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 335: 99-103.
29. Kautter DA, Solomon HM (1977) Collaborative study of a method for the detection of Clastridium botolinum and its toxins in foods. J Assoc Off Anal Chem 60: 541-545.
30. Sharma SK, Fcrreira JL, Eblen BS, Whiting RC (2006) Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzymelinked immunosorbent assay with digoxigenin-labeled antibodies. Appl Environ Microbiol 72: 1231-1238.
31. Sugiyama H (1980) Clostridium botulinum neurotoxin. Microbiol Rev 44: 419-448.
32. Ferreira JL, Maslanka S, Johnson E, Goodnough M (2003) Detection of botulinal neurotoxins A, B, E, and F by amplified enzyme-linked immunosorbent assay: collaborative study. J AOAC Int 86: 314-331.
33. Liu W, Montana V, Chapman ER, Mohideen U, Parpura V (2003) Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A 100: 13621-13625.
34. Dong M, Tepp WH, Johnson EA, Chapman ER (2004) Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci U S A 101: 14701-14706.
35. Varnum SM, Warner MG, Dockendorff B, Anheier Jr NC, Lou Jc, et al. (2006) Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Analytica Chimica Acta 570: 137-143.
36. Kalb SR, Moura H, Boyer AE, McWilliams LG, Pirkle JL, et al. (2006) The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. Anal Biochem 351: 84-92.
37. Kalb SR, Goodnough MC, Malizio CJ, Pirkle JL, Barr JR (2005) Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics. Anal Chem 77: 6140-6146.
38. Boyer AE, Moura H, Woolfitt AR, Kalb SR, McWilliams LG, et al. (2005) From the mouse to the mass spectrometer: detection and difterentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal Chem 77: 3916-3924.
39. Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, et al. (2005) Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 11: 1578-1583.
40. Chao HY, Wang YC, Tang SS, Liu HW (2004) A highly sensitive immuno-polymerase chain reaction assay for Clostridium botulinum neurotoxin type A. Toxicon 43: 27-34.
41. Mason JT, Xu L, Sheng ZM, O'Leary TJ (2006) A liposome-PCR assay for the ultrasensitive detection of biological toxins. Nat Biotechnol 24: 555-557.
42. Mason JT, Xu L, Sheng ZM, He J, O'Leary TJ (2006) Liposome polymerase chain reaction assay for the sub-attomolar detection of cholera toxin and botulinum neurotoxin type A. Nature Protocols 1: 2003-2011.
43. Ekong TA, McLellan K, Sesardic D (1995) Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. J Immunol Methods 180: 181-191.
44. Centers for Disease Control and Prevention (1998) Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, CDC and Prevention. pp 1-42.
45. Schantz E, Kautter DA (1978) Standardized assay for Clostridium botulinum toxins. J ACAC Int 61: 96-99.
46. Marks JD (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 19 Suppl 8: S101-108.
47. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, et al. (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25: 107-116.
48. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, et al. (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318: 1343-1351.
49. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, et al. (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75: 3043-3054.
50. Simpson LL, Maksymowych AB, Han S (2001) The role of zinc binding in the biological activity of botulinum toxin. J Biol Chem 276: 27034-27041.
51. Ahmed SA, Ludivico ML, Smith LA (2004) Factors affecting autocatalysis of botulinum A neurotoxin light chain. Protein J 23: 445-451.
52. Ahmed SA, Byrne MP, Jensen M, Hines HE, Brueggemann E, et al. (2001) Enzymatic autocatalysis of botulinum A neurotoxin light chain. J Protein Chem 20: 221-231.
53. Kukreja P, Singh B (2005) Biologically active novel conformational state of botulinum, the most poisonous poison. J Biol Chem 280: 39346-39352.
54. Losikoff ME (1978) Establishment of a heat inactivation curve for Clostridium botulinum 62A toxin in beef broth. Appl Environ Microbiol 36: 386-388.
55. Schmidt JJ, Stafford RG (2003) Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol 69: 297-303.
56. Samsonov VG, Mirgorodskaia OA, Moskvichev BV (1979) [Kinetics of low molecular weight substrate hydrolysis by immobilized trypsin]. Biokhimiia 44: 1192-1196.